An antibody treatment successfully protected nonhuman primates against the deadly Marburg and Ravn viruses even when given five days after becoming infected, according to the latest findings of a collaborative team from The University of Texas Medical Branch at Galveston, Mapp Biopharmaceutical Inc., and Vanderbilt University. The findings are now available in Science Translational Medicine.
There are currently no vaccines or drugs approved for human use to protect against the Marburg and Ravn viruses. These two filoviruses, which are in the same virus family as Ebola, cause severe and often lethal disease in people. The average case fatality rate of Marburg virus disease since the first recognized outbreak in 1967 is 80 percent.
Monoclonal antibodies are a technology that is currently in wide use for treating autoimmune diseases and cancers. There are more than 45 monoclonal antibodies approved by the U.S. Food and Drug Administration and European Medicines Agency.
“In this paper, we demonstrated that one monoclonal antibody is able to protect up to 100 percent of Marburg or Ravn virus-infected non-human primates when the antibody treatment is given up to five days following exposure to a lethal amount of the virus,” said UTMB’s Thomas Geisbert, professor in the department of microbiology and immunology. “These findings extend the growing body of evidence that monoclonal antibodies can provide protection during advanced stages of disease with highly dangerous viruses and could be useful during an epidemic.”
The study was conducted in Biosafety Level (BSL)-4 at UTMB’s Galveston National Laboratory. BSL-4 is a highly-restricted area where scientists wear positive pressure protective suits and study pathogens that cause severe and often fatal diseases. UTMB has the only functioning BSL-4 laboratory located on an American university campus.
The 2013 to 2016 Ebola virus epidemic highlighted the troubling lack of preventive or treatment options for filoviruses. Some of the therapeutics used to treat those infected with Ebola were developed and tested in the GNL.
“The level of protection observed by Dr. Geisbert’s team with this antibody is very impressive. We plan to advance this product towards human safety testing as quickly as possible,” said Larry Zeitlin, president of Mapp Biopharmaceutical Inc.
Other authors of this paper include UTMB’s Chad Mire, Joan Geisbert, Viktoriya Borisevich, Karla Fenton, Krystle Agans and Daniel Deer; Andrew Flyak and James Crowe, Jr. from Vanderbilt University Medical Center; Herta Steinkellner from the University of Natural Resources and Life Sciences in Vienna and Ognian Bohorov, Natasha Bohorova, Charles Goodman, Andrew Hiatt, Do Kim, Michael Pauly, Jesus Velasco and Kevin Whaley.
This study was supported by the Department of Health and Human Services, National Institutes of Health and BSL-4 operations support of the Galveston National Laboratory.
@3cowboyfans We are so glad to hear this. Sending our best wishes your way.
"What I like about MD Anderson is that everybody there is zeroing in on one entity: cancer." #CancerMoonshot #endcancer https://t.co/qKeu2MMCRw
You might jokingly say your child is addicted to video games, but this year the @WHO added gaming disorder to their list of diseases. Learn what signs you should watch for. https://t.co/86P9JnVVHj
VA Homeless Veteran Community Employment Services help Veterans get back on track — and back into the workforce. Learn more at https://t.co/rU7ZR6K4MW
Baylor College of MedicineBaylorCollegeOfMedicine
Allergies can cause havoc not only on your sinuses but also on your skin. Dr. Rajani Katta with the Department of Medicine explains. #allergies
Tips for staying healthy in jobs popular with the Veteran community https://t.co/lCaWVflETV via #VAntagePoint
Today’s #VeteranOfTheDay is @USNavy Veteran Charles F. Houston https://t.co/XBIPYIGccY
U.S. Department of Veterans AffairsVeteransAffairs
Today’s #VeteranOfTheDay is Navy Veteran Charles F. Houston. Charles served from 1941 to 1945 during World War II. Charles was born in Philadelphia, Pennsylvania and enlisted in the Navy on Sept. 16, 1941 at the age of 23. His training was in Norfolk, Virginia and he later served in Great Lakes, Illinois and on the USS De Haven. Charles was a member of the V6, or General Service and Specialists, unit. Charles now resides in Bluebell, Pennsylvania and is celebrating his 100th birthday today, March 23, 2018. Thank you for your service, Charles, and Happy Birthday!
CHI St Luke's Health@CHI_StLukes
RT @DrThaoGalvan: Dr Terry Box tells of his riveting transition from leading a liver transplant program to becoming a liver transplant pati…
TAMU Health Sciences@TAMHSC
Age successfully with this guide to #SeniorHealth: https://t.co/iXuYtxaSoh #Health #Aging #TAMHSC
RT @bcm_careerdev: Q. Andy Guo, PhD introducing internship opportunities at Baylor Licensing Group @bcmhouston & careers in technology tran…
Don’t have time for a long run? Consider an interval treadmill workout https://t.co/7rfoHESbjS
University of Houston@UHouston
RT @UHpres: Breaking ground for Technology Building at UH Sugar Land... https://t.co/3nNwEZfZPI
Watch how a second opinion revealed Gail Barr had stage IV #breastcancer and led her to find success with a #clinicaltrial. #bcsm #endcancer https://t.co/bMK3nuXlRN
University of Houston@UHouston
RT @CoachApplewhite: What a day on campus with Coog legends @sonofbum and @casekeenum7 ! #UHFBclinic #GoCoogs https://t.co/UZIzwEqELj